Novo Nordisk A/S (NYSE:NVO) Stock Position Decreased by Zevin Asset Management LLC

Zevin Asset Management LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,292 shares of the company’s stock after selling 1,679 shares during the period. Zevin Asset Management LLC’s holdings in Novo Nordisk A/S were worth $4,917,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Patten & Patten Inc. TN acquired a new stake in Novo Nordisk A/S in the first quarter worth $258,000. Resurgent Financial Advisors LLC boosted its stake in Novo Nordisk A/S by 184.4% during the 1st quarter. Resurgent Financial Advisors LLC now owns 1,587 shares of the company’s stock valued at $204,000 after purchasing an additional 1,029 shares during the period. Davis R M Inc. bought a new position in Novo Nordisk A/S in the 1st quarter worth about $201,000. Atlanta Consulting Group Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $509,000. Finally, Arjuna Capital boosted its position in shares of Novo Nordisk A/S by 25.0% during the first quarter. Arjuna Capital now owns 53,400 shares of the company’s stock worth $6,857,000 after buying an additional 10,696 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 3.4 %

NVO stock opened at $101.74 on Monday. The firm has a market cap of $456.56 billion, a PE ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a 50 day simple moving average of $118.58 and a 200 day simple moving average of $129.59.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NVO. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.